Airway and peripheral uPAR is elevated in asthma, and identifies a severe, non-atopic subset of patients
Airway and peripheral uPAR is elevated in asthma, and identifies a severe, non-atopic subset of patients
Rationale: Genetic polymorphisms in the asthma susceptibility gene, urokinase plasminogen activator receptor (uPAR/PLAUR) have been associated with lung function decline and uPAR blood levels in asthma subjects. Preliminary studies have identified uPAR elevation in asthma; however, a definitive study regarding which clinical features of asthma uPAR may be driving is currently lacking.
Objectives: We aimed to comprehensively determine the uPAR expression profile in asthma and control subjects utilizing bronchial biopsies and serum, and to relate uPAR expression to asthma clinical features.
Methods: uPAR levels were determined in control (n = 9) and asthmatic (n = 27) bronchial biopsies using immunohistochemistry, with a semi-quantitative score defining intensity in multiple cell types. Soluble-cleaved (sc) uPAR levels were determined in serum through ELISA in UK (cases n = 129; controls n = 39) and Dutch (cases n = 514; controls n = 96) cohorts.
Measurements and main results: In bronchial tissue, uPAR was elevated in inflammatory cells in the lamina propria (P = 0.0019), bronchial epithelial (P = 0.0002) and airway smooth muscle cells (P = 0.0352) of patients with asthma, with uPAR levels correlated between the cell types. No correlation with disease severity or asthma clinical features was identified. scuPAR serum levels were elevated in patients with asthma (1.5-fold; P = 0.0008), and we identified an association between high uPAR serum levels and severe, nonatopic disease.
Conclusions: This study provides novel data that elevated airway and blood uPAR is a feature of asthma and that blood uPAR is particularly related to severe, nonatopic asthma. The findings warrant further investigation and may provide a therapeutic opportunity for this refractory population.
473-482
Portelli, Michael A.
704a16d0-d1e3-46a8-986c-cb6ef81a53f9
Moseley, Christopher
8bb94ddf-64b3-4c3b-9011-07b3706d66cd
Stewart, Ceri E.
39812638-540b-4ecf-97bf-b763c826c8b5
Postma, Dirkje S.
23c1567d-a264-48a1-9ab4-01beda374e42
Howarth, Peter
ff19c8c4-86b0-4a88-8f76-b3d87f142a21
Warner, Jane A.
8571b049-31bb-4a2a-a3c7-4184be20fe25
Holloway, John W.
4bbd77e6-c095-445d-a36b-a50a72f6fe1a
Koppelman, Gerard H.
8d04aab8-5795-4e62-b64a-de7e368c0d1d
Brightling, Chris
a4ba69e8-3c26-42ba-9a64-2b44e93c13d0
Sayers, Ian
8595fc2e-102b-406c-ba26-269b8bdba786
17 February 2017
Portelli, Michael A.
704a16d0-d1e3-46a8-986c-cb6ef81a53f9
Moseley, Christopher
8bb94ddf-64b3-4c3b-9011-07b3706d66cd
Stewart, Ceri E.
39812638-540b-4ecf-97bf-b763c826c8b5
Postma, Dirkje S.
23c1567d-a264-48a1-9ab4-01beda374e42
Howarth, Peter
ff19c8c4-86b0-4a88-8f76-b3d87f142a21
Warner, Jane A.
8571b049-31bb-4a2a-a3c7-4184be20fe25
Holloway, John W.
4bbd77e6-c095-445d-a36b-a50a72f6fe1a
Koppelman, Gerard H.
8d04aab8-5795-4e62-b64a-de7e368c0d1d
Brightling, Chris
a4ba69e8-3c26-42ba-9a64-2b44e93c13d0
Sayers, Ian
8595fc2e-102b-406c-ba26-269b8bdba786
Portelli, Michael A., Moseley, Christopher, Stewart, Ceri E., Postma, Dirkje S., Howarth, Peter, Warner, Jane A., Holloway, John W., Koppelman, Gerard H., Brightling, Chris and Sayers, Ian
(2017)
Airway and peripheral uPAR is elevated in asthma, and identifies a severe, non-atopic subset of patients.
Allergy, 72 (3), .
(doi:10.1111/all.13046).
Abstract
Rationale: Genetic polymorphisms in the asthma susceptibility gene, urokinase plasminogen activator receptor (uPAR/PLAUR) have been associated with lung function decline and uPAR blood levels in asthma subjects. Preliminary studies have identified uPAR elevation in asthma; however, a definitive study regarding which clinical features of asthma uPAR may be driving is currently lacking.
Objectives: We aimed to comprehensively determine the uPAR expression profile in asthma and control subjects utilizing bronchial biopsies and serum, and to relate uPAR expression to asthma clinical features.
Methods: uPAR levels were determined in control (n = 9) and asthmatic (n = 27) bronchial biopsies using immunohistochemistry, with a semi-quantitative score defining intensity in multiple cell types. Soluble-cleaved (sc) uPAR levels were determined in serum through ELISA in UK (cases n = 129; controls n = 39) and Dutch (cases n = 514; controls n = 96) cohorts.
Measurements and main results: In bronchial tissue, uPAR was elevated in inflammatory cells in the lamina propria (P = 0.0019), bronchial epithelial (P = 0.0002) and airway smooth muscle cells (P = 0.0352) of patients with asthma, with uPAR levels correlated between the cell types. No correlation with disease severity or asthma clinical features was identified. scuPAR serum levels were elevated in patients with asthma (1.5-fold; P = 0.0008), and we identified an association between high uPAR serum levels and severe, nonatopic disease.
Conclusions: This study provides novel data that elevated airway and blood uPAR is a feature of asthma and that blood uPAR is particularly related to severe, nonatopic asthma. The findings warrant further investigation and may provide a therapeutic opportunity for this refractory population.
Text
all13046.pdf
- Version of Record
More information
Accepted/In Press date: 9 September 2016
e-pub ahead of print date: 5 October 2016
Published date: 17 February 2017
Organisations:
Human Development & Health, Clinical & Experimental Sciences
Identifiers
Local EPrints ID: 401119
URI: http://eprints.soton.ac.uk/id/eprint/401119
ISSN: 0105-4538
PURE UUID: 62961d91-8e0d-4f6d-a06d-b32785c8e13b
Catalogue record
Date deposited: 10 Oct 2016 10:13
Last modified: 13 Nov 2021 02:38
Export record
Altmetrics
Contributors
Author:
Michael A. Portelli
Author:
Christopher Moseley
Author:
Ceri E. Stewart
Author:
Dirkje S. Postma
Author:
Gerard H. Koppelman
Author:
Chris Brightling
Author:
Ian Sayers
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
